Tesofensine

Prader-Willi Syndrome

SanionaSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

20 Active assets in the Prader-Willi Syndrome cohort.

Asset / Sponsor	Phase	Rating
Genotropin Corporacion Parc Tauli	Phase 4	BBB
Oxytocin University Hospital, Toulouse	Phase 2/3	BBB
Dccr Soleno Therapeutics, Inc.	Phase 3	BB
Omnitrope University Hospital, Toulouse	Phase 4	BB
Guanfacine Maimonides Medical Center	Phase 4	BB

View all 36 →

Same molecule, other indications

Tesofensine is also rated in:

obesity disorderDormant

B

Indicative ·

59 / 100

acquired hypothalamic obesityDormant

B

Indicative ·

57 / 100

Parkinson diseaseDormant

CCC

Indicative ·

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.